date:Dec 14, 2022
general meetings of the two companies scheduled for the first half of 2023.
Once the merger is completed, Novo Holdings will own 22%, Chr. Hansens free float shareholders will own 35% and Novozymes free float shareholders will own 44% of the combined groups total shared capital. The new group is predicted to post an organic revenue of growth of 6-8% through to 2025.
The two companies are a perfect match, Chr. Hansen with its expertise in microbials and Novozymes with its background in enzymes